ThromboGenics Plunges on Jetrea Sales Forecast: Brussels Mover

ThromboGenics NV, the Belgian eye-drug developer, fell as much as 30 percent after forecasting that sales of its only approved product won’t increase in the second half of the year, missing analysts’ estimates.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.